Inrebic
Primary Myelofibrosis, Primary Myelofibrosis, Myelodysplastic Syndromes + 1 more
Treatment
6 FDA approvals
1 Active Study for Inrebic
Treatment for
Primary Myelofibrosis
What is Inrebic
Fedratinib
The Generic name of this drug
Treatment Summary
Fedratinib is a medication used to treat myelofibrosis, a rare bone marrow cancer. It is an anilinopyrimidine derivative and works by blocking a certain enzyme in the body that helps the cancer grow. Fedratinib was approved by the FDA in 2019 and is also known by the names SAR302503 and TG101348.
Inrebic
is the brand name
Inrebic Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Inrebic
Fedratinib
2019
1
Approved as Treatment by the FDA
Fedratinib, otherwise called Inrebic, is approved by the FDA for 6 uses including Secondary Myelofibrosis and Primary Myelofibrosis (PMF) .
Secondary Myelofibrosis
Primary Myelofibrosis (PMF)
IPSS High Risk
Primary Myelofibrosis
Myelodysplastic Syndromes
Primary Myelofibrosis
Effectiveness
How Inrebic Affects Patients
Fedratinib is a drug that stops cells from dividing and causes them to die. Some of the possible side effects of taking this medication include low red blood cell count, low platelet count, stomach pain or nausea, liver damage, and high levels of enzymes in the blood. If any of these occur, the dose may need to be lowered or the drug may need to be stopped or a transfusion may be necessary.
How Inrebic works in the body
Fedratinib stops the Janus Activated Kinase 2 (JAK2) enzyme. JAK2 is involved in the growth of myeloproliferative neoplasms, such as myelofibrosis. Fedratinib blocks the action of JAK2, which stops the cell from dividing and triggers the process of cell death, known as apoptosis.
When to interrupt dosage
The measure of Inrebic depends upon the determined affliction, such as Secondary Myelofibrosis, Primary Myelofibrosis and IPSS High Risk. The dosage is contingent upon the method of delivery (e.g. Oral or Capsule - Oral) featured in the table beneath.
Condition
Dosage
Administration
Myelodysplastic Syndromes
, 100.0 mg
Oral, Capsule, Capsule - Oral,
IPSS High Risk
, 100.0 mg
Oral, Capsule, Capsule - Oral,
Primary Myelofibrosis
, 100.0 mg
Oral, Capsule, Capsule - Oral,
Primary Myelofibrosis
, 100.0 mg
Oral, Capsule, Capsule - Oral,
Warnings
There are 20 known major drug interactions with Inrebic.
Common Inrebic Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Fedratinib.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Fedratinib.
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Fedratinib.
Axitinib
Major
The serum concentration of Axitinib can be increased when it is combined with Fedratinib.
Bendamustine
Major
The serum concentration of Bendamustine can be increased when it is combined with Fedratinib.
Inrebic Toxicity & Overdose Risk
Data about overdosing on fedratinib is not available. People taking 680mg/day have experienced more serious side effects including anemia, low platelet count, gastrointestinal issues, liver problems, and high levels of amylase and lipase. Treatment for these effects includes reducing the dose or stopping fedratinib and managing symptoms.
Inrebic Novel Uses: Which Conditions Have a Clinical Trial Featuring Inrebic?
Presently, 14 active investigations are assessing the potential of Inrebic to ameliorate Primary Myelofibrosis, IPSS Risk Category Intermediate-2 and Secondary Myelofibrosis.
Condition
Clinical Trials
Trial Phases
Primary Myelofibrosis
0 Actively Recruiting
Myelodysplastic Syndromes
0 Actively Recruiting
Primary Myelofibrosis
1 Actively Recruiting
Phase 2
IPSS High Risk
0 Actively Recruiting
Patient Q&A Section about inrebic
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What type of drug is Inrebic?
"Inrebic is a prescription medicine that is used to treat the symptoms associated with myelofibrosis. It may be used alone or in combination with other medications. Inrebic belongs to a class of drugs call hematologic kinase inhibitors and antineoplastic JAK inhibitors. The safety and efficacy of Inrebic has not been established in children."
Answered by AI
Is Inrebic a chemo drug?
"The drug Fedratinib is also known by the trade name INREBIC®. In some cases, health care professionals may use the trade name INREBIC® when referring to the generic drug name Fedratinib. Fedratinib is classified as an anti-cancer ("antineoplastic") targeted agent, specifically a "JAK2 inhibitor"."
Answered by AI
How is Inrebic administered?
"The recommended dosage of INREBIC for patients with a baseline platelet count of greater than or equal to 50 x 109/L is 400 mg taken orally once daily. INREBIC can be taken with or without food, but taking it with a high fat meal may reduce the incidence of nausea and vomiting."
Answered by AI
Who makes Inrebic?
"Celgene Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis."
Answered by AI